Src kinases as targets for B cell acute lymphoblastic leukaemia therapy

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 2, 2005, Pages 329-341

  Li, Shaoguang ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

B cell acute lymphoblastic leukemia (B ALL); BCR ABL; Oncogene; Signalling pathway; Src kinase; Tyrosine kinase inhibitor

Indexed keywords

[4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; BCR ABL PROTEIN; CGP 76030; DASATINIB; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; B CELL LEUKEMIA; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ERADICATION THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT PLANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, B-CELL, ACUTE; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 18144426133     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.2.329     Document Type: Review

References (114)

1. HU Y, LIU Y, PELLETIER S et al.: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. (2004) 36:453-461.
2. DEININGER MW, GOLDMAN JM, MELO JV: The molecular biology of chronic myeloid leukemia. Blood (2000) 96:3343-3356.
3. PANE F, FRIGERI F, SINDONA M et al.: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood (1996) 88:2410-2414.
4. SAWYERS CL: Chronic myeloid leukemia. N. Engl. J. Med. (1999) 340:1330-1340.
5. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
6. TOWATARI M, ADACHI K, KATO H, SAITO H: Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood (1991) 78:2178-2181.
7. SILL H, GOLDMAN JM, CROSS NC: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood (1995) 85:2013-2016.
8. FEINSTEIN E, CIMINO G, GALE RP et al.: p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA. (1991) 88:6293-6297.
9. DEUTSCH E, DUGRAY A, ABDULKARIM B et al.: BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood (2001) 97:2084-2090.
10. TAKEDA N, SHIBUYA M, MARU Y: The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc. Natl. Acad. Sci. USA (1999) 96:203-207.
11. CANITROT Y, LAUTIER D, LAURENT G et al.: Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene (1999) 18:2676-2680.
12. SLUPIANEK A, SCHMUTTE C, TOMBLINE G et al.: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell (2001) 8:795-806.
13. DIEROV J, DIEROVA R, CARROLL M: BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell (2004) 5:275-285.
14. HUETTNER CS, ZHANG P, VAN ETTEN RA, TENEN DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. (2000) 24:57-60.
15. CALABRETTA B, PERROTTI D: The biology of CML blast crisis. Blood (2004) 103:4010-22.
16. LOWELL CA, SORIANO P: Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev. (1996) 10:1845-1857.
17. BROWN MT, COOPER JA: Regulation, substrates and functions of src. Biochem. Biophys. Acta (1996) 1287:121-149.
18. BRIGGS SD, SHARKEY M, STEVENSON M, SMITHGALL TE: SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. J. Biol Chem. (1997) 272:17899-17902.
19. MOAREFI I, LAFEVRE-BERNT M, SICHERI F et al.: Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature (1997) 385:650-653.
20. HARDER KW, PARSONS LM, ARMES J et al.: Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity (2001) 15:603-615.
21. WILLMAN CL, STEWART CC, LONGACRE TL et al.: Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. Blood (1991) 77:726-734.
22. TORIGOE T, O'CONNOR R, SANTOLI D, REED JC: Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines. Blood (1992) 80:617-624.
23. ERNOULD AP, FERRY G, BARRET JM, GENTON A, BOUTIN JA: Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60. Int. J. Pept. Protein Res. (1994) 43:496-504.
24. KATAGIRI K, YOKOYAMA KK, YAMAMOTO T et al.: Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J. Biol. Chem. (1996) 271:11557-11562.
25. LI Y, SHEN BF, KARANES C, SENSENBRENNER L, CHEN B: Association between Lyn protein tyrosine kinase (p53/56lyn) and the beta subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human megakaryocytic leukemia cell line (M-07e). J. Immunol. (1995) 155:2165-2174.
26. FISCHER S, WENDLING F, BOULET I et al.: Elevated level of p60c-src in virus-transformed murine megakaryocytic cell lines. Oncogene (1989) 4:901-905.
27. ZARN JA, ZIMMERMANN SM, PASS MK, WAIBEL R, STAHEL RA: Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem. Biophys. Res. Commun. (1996) 225:384-391.
28. TILBROOK PA, PALMER GA, BITTORF T et al.: Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. Cancer Res. (2001) 61:2453-458.
29. WAKI M, KITANAKA A, KAMANO H et al.: Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression. Biochem. Biophys. Res. Commun. (1994) 201:1001-1007.
30. YAMAGUCHI M, TANAKA T, WAKI M et al.: Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells. Leukemia (1997) 11:497-503.
31. KRUGER A, ANDERSON SM: The v-src oncogene blocks the differentiation of a murine myeloid progenitor cell line and induces a tumorigenic phenotype. Oncogene (1991) 6:245-256.
32. O'CONNOR R, TORIGOE T, REED JC, SANTOLI D: Phenotypic changes induced by interleukin-2 (IL-2) and IL-3 in an immature T lymphocytic leukemia are associated with regulated expression of IL-2 receptor beta chain and of protein tyrosine kinases LCK and LYN. Blood (1992) 80:1017-1025.
33. TORIGOE T, O'CONNOR R, FAGARD R et al.: Interleukin 4 inhibits IL-2-induced proliferation of a human T-leukemia cell line without interfering with p56-LCK kinase activation. Cytokine (1992) 4:369-376.
34. BURNETT RC, DAVID JC, HARDEN AM et al.: The LCK gene is involved in the t(1;7)(p34;q34) in the T-cell acute lymphoblastic leukemia derived cell line, HSB-2. Genes Chromosomes Cancer (1991) 3:461-467.
35. LYNCH SA, BRUGGE JS, FROMOWITZ F et al.: Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas. Leukemia (1993) 7:1416-1422.
36. ABRAHAM KM, LEVIN SD, MARTH JD, FORBUSH KA, PERLMUTTER RM: Thymic tumorigenesis induced by overexpression of p56lck. Proc. Natl. Acad. Sci. USA (1991) 88:3977-3981.
37. MALEK SN, DORDAI DI, REIM J, DINTZIS H, DESIDERIO S: Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc. Natl. Acad. Sci. USA (1998) 95:7351-7356.
38. UCKUN FM, BURKHARDT AL, JARVIS L et al.: Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. (1993) 268:21172-21184.
39. MYERS DE, JUN X, WADDICK KG et al.: Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc. Natl. Acad. Sci. USA (1995) 92:9575-9579.
40. UCKUN FM, EVANS WE, FORSYTH CJ et al.: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (1995) 267:886-891.
41. SAWYERS CL: Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin. Haematol. (1997) 10:223-231.
42. ANDERSON SM, MLADENOVIC J: The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood (1996) 87:238-244.
43. HARIHARAN IK, ADAMS JM, CORY S: bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res. (1988) 3:387-399.
44. SKORSKI T, NIEBOROWSKA-SKORSKA M, WLODARSKI P et al.: Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA (1996) 93:13137-13142.
45. HONDA H, HIRAI H: Model mice for BCR/ABL-positive leukemias. Blood Cells Mol. Dis. (2001) 27:265-278.
46. NESHAT MS, RAITANO AB, WANG HG, REED JC, SAWYERS CL: The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol. (2000) 20:1179-1186.
47. MAJEWSKI M, NIEBOROWSKA-SKORSKA M, SALOMONI P et al.: Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. (1999) 59:2815-2819.
48. SANCHEZ-GARCIA I, MARTIN-ZANCA D: Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol (1997) 267:225-228.
49. DUBREZ L, EYMIN B, SORDET O et al.: BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood (1998) 91:2415-2422.
50. AMARANTE-MENDES GP, NAEKYUNG KIM C, LIU L et al.: Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood (1998) 91:1700-1705.
51. MCGAHON AJ, NISHIOKA WK, MARTIN SJ et al.: Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. (1995) 270:22625-22631.
52. SKORSKI T, BELLACOSA A, NIEBOROWSKA-SKORSKA M et al.: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. (1997) 16:6151-6161.
53. JONULEIT T, VAN DER KUIP H, MIETHING C et al.: Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 96:1933-1939.
54. PARADA Y, BANERJI L, GLASSFORD J et al.: BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J. Biol. Chem. (2001) 276:23572-23580.
55. GOETZ AW, VAN DER KUIP H, MAYA R, OREN M, AULITZKY WE: Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. Cancer Res. (2001) 61:7635-7641.
56. DANHAUSER-RIEDL S, WARMUTH M, DRUKER BJ, EMMERICH B, HALLEK M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. (1996) 56:3589-3596.
57. WARMUTH M, BERGMANN M, PRIESS A et al.: The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. (1997) 272:33260-33270.
58. LIONBERGER JM, WILSON MB, SMITHGALL TE: Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. (2000) 275:18581-18585.
59. ANDERSON SM, JORGENSEN B: Activation of src-related tyrosine kinases by IL-3. J. Immunol. (1995) 155:1660-1670.
60. DALEY GQ, BALTIMORE D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA. (1988) 85:9312-9316.
61. KABAROWSKI JH, ALLEN PB, WIEDEMANN LM: A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. (1994) 13:5887-5895.
62. WILSON MB, SCHREINER SJ, CHOI HJ, KAMENS J, SMITHGALL TE: Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene (2002) 21:8075-8088.
63. WARMUTH M, SIMON N, MITINA O et al.: Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood (2003) 101:664-672.
64. TAUCHI T, FENG GS, SHEN R et al.: SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J. Biol. Chem. (1994) 269:15381-15387.
65. BRUECHER-ENCKE B, GRIFFIN JD, NEEL BG, LORENZ U: Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia (2001) 15:1424-1432.
66. DAIGLE I, YOUSEFI S, COLONNA M, GREEN DR, SIMON HU: Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat. Med. (2002) 8:61-67.
67. GARDAI S, WHITLOCK BB, HELGASON C et al.: Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J. Biol. Chem. (2002) 277:5236-5246.
68. YANG W, MCKENNA SD, JIAO H et al.: SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased lyn kinase activity. Exp. Hematol. (1998) 26:1126-1132.
69. VAN ZANT G, SHULTZ L: Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). Exp. Hematol. (1989) 17:81-87.
70. HELGASON CD, DAMEN JE, ROSTEN P et al.: Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. (1998) 12:1610-1620.
71. LIU Q, SASAKI T, KOZIERADZKI I et al.: SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. (1999) 13:786-791.
72. PARK H, WAHL MI, AFAR DE et al.: Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity (1996) 4:515-525.
73. RAWLINGS DJ, SCHARENBERG AM, PARK H et al.: Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 271:822-825.
74. DEININGER M: Src kinases in Ph+ lymphoblastic leukemia. Nat. Genet. (2004) 36:440-441.
75. LI S, ILARIA RL, JR., MILLION RP, DALEY GQ, VAN ETTEN RA: The P190, P210, and p230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. (1999) 189:1399-1412.
76. ROUMIANTSEV S, DE AOS IE, VARTICOVSKI L, ILARIA RL, VAN ETTEN RA: The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood (2001) 97:4-13.
77. KLEJMAN A, SCHREINER SJ, NIEBOROWSKA-SKORSKA M et al.: The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO. J. (2002) 21:5766-5774.
78. SEXL V, PIEKORZ R, MORIGGL R et al.: Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of stat5. Blood (2000) 96:2277-2283.
79. VAN ETTEN RA: Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk. Res. (2004) 28(Suppl. 1):21-28.
80. SATTLER M, MOHI MG, PRIDE YB et al.: Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 1:479-492.
81. DRUKER BJ, LYDON NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. (2000) 105:3-7.
82. LYDON NB, DRUKER BJ: Lessons learned from the development of imatinib. Leuk. Res. (2004) 28 (Suppl. 1):S29-S38.
83. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
84. MARLEY SB, DEININGER MW, DAVIDSON RJ, GOLDMAN JM, GORDON MY: The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. (2000) 28:551-557.
85. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
86. WEISBERG E, GRIFFIN JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 95:3498-3505.
87. LE COUTRE P, TASSI E, VARELLA-GARCIA M et al.: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood (2000) 95:1758-1766.
88. MAHON FX, DEININGER MW, SCHULTHEIS B et al.: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood (2000) 96:1070-1079.
89. SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutants confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crise chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
90. BRANFORD S, RUDZKI Z, WALSH S et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood (2002) 99:3472-3475.
91. VON BUBNOFF N, SCHNELLER F, PESCHEL C, DUYSTER J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet (2002) 359:487-491.
92. TALPAZ M, SAWYERS CL, KANTARJAIN H et al.: Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR/ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Oncologist (2000) 5:282-283 (Abstr.).
93. SHAH NP, TRAN C, LEE FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
94. O'HARE T, POLLOCK R, STOFFREGEN EP et al.: Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood (2004) 104:2532-2539.
95. PTASZNIK A, NAKATA Y, KALOTA A, EMERSON SG, GEWIRTZ AM: Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. (2004) 10:1187-1189.
96. TAUCHI T, OHYASHIKI K: Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res. (2004) 28 (Suppl. 1):S39-S45.
97. DONATO NJ, WU JY, STAPLEY J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 101:690-698.
98. REYA T, MORRISON SJ, CLARKE MF, WEISSMAN IL: Stem cells, cancer, and cancer stem cells. Nature (2001) 414:105-111.
99. JAMIESON CH, AILLES LE, DYLLA SJ et al.: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med (2004) 351:657-667.
100. BONNET D, DICK JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. (1997) 3:730-737.
101. LESSARD J, SAUVAGEAU G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 423:255-260.
102. PARK IK, QIAN D, KIEL M et al.: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 423:302-305.
103. WILSON A, MURPHY MJ, OSKARSSON T et al.: c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. (2004) 18:2747-2763.
104. REYA T, DUNCAN AW, AILLES L et al.: A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature (2003) 423:409-414.
105. WILLERT K, BROWN JD, DANENBERG E et al.: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature (2003) 423:448-452.
106. JANOSSY G, ROBERTS M, GREAVES MF: Target cell in chronic myeloid leukaemia and its relationship to acute lymphoid leukaemia. Lancet (1976) 2:1058-1061.
107. SCHROEDER JA, ADRIANCE MC, THOMPSON MC, CAMENISCH TD, GENDLER SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene (2003) 22:1324-1332.
108. HARAGUCHI K, NISHIDA A, ISHIDATE T, AKIYAMA T: Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src. Biochem. Biophys. Res. Commun. (2004) 313:841-844.
109. HUGHES TP, KAEDA J, BRANFORD S et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. (2003) 349:1423-1432.
110. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348:994-1004.
111. LIN F, DRUMMOND M, O'BRIEN S et al.: Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood (2003) 102:1143.
112. DRUMMOND MW, LUSH CJ, VICKERS MA et al.: Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia (2003) 17:463-465.
113. SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogeneic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99:3530-3539.
114. KANTARJIAN HM, CORTES J, O'BRIEN S et al.: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood (2002) 99:3547-3553.